同步 IV 期结直肠癌患者抗癌药物敏感性检测的临床潜力。
Clinical potential of the anticancer drug sensitivity test for patients with synchronous stage IV colorectal cancer.
机构信息
Department of Gastroenterological Surgery, Shiga University of Medical Science, Seta, Tsukinowa-cho, Otsu, Shiga, 520-2192, Japan.
出版信息
Cancer Chemother Pharmacol. 2013 Jul;72(1):217-22. doi: 10.1007/s00280-013-2189-7. Epub 2013 Jun 1.
PURPOSE
We retrospectively evaluated the clinical efficacy and feasibility of a collagen gel droplet-embedded culture drug sensitivity test (CD-DST) to guide therapy for patients with stage IV colorectal cancer (CRC).
METHODS
We investigated 38 patients with stage IV CRC. All patients were younger than 85 years and had untreated evaluable metastatic lesions. The primary tumors were surgically resected, and the tissue samples were investigated by CD-DST. Patients treated with in vitro sensitive drugs were defined as Group A (n = 14), while those treated with in vitro non-sensitive drugs were defined as Group B (n = 24). We evaluated response rate (RR), progression-free survival (PFS), and overall survival (OS).
RESULTS
RR was 85.71 % in Group A and 41.67 % in Group B (p = 0.0079). The median PFS was 696.5 days in Group A and 297.5 days in Group B (p = 0.0326). The median OS was 1,023.4 days in Group A and 518.5 days in Group B (p = 0.0061).
CONCLUSIONS
The CD-DST can define chemoresistant and chemosensitive tumors. The use of CD-DST might be one of the tools to supplement informed consent prior to initiation of therapy.
目的
我们回顾性评估胶原凝胶微滴嵌入培养药敏试验（CD-DST）指导 IV 期结直肠癌（CRC）患者治疗的临床疗效和可行性。
方法
我们研究了 38 例 IV 期 CRC 患者。所有患者年龄均小于 85 岁，且均存在未经治疗的可评估转移病灶。对原发肿瘤进行手术切除，并通过 CD-DST 对组织样本进行研究。对接受体外敏感药物治疗的患者定义为 A 组（n=14），而对接受体外不敏感药物治疗的患者定义为 B 组（n=24）。我们评估了反应率（RR）、无进展生存期（PFS）和总生存期（OS）。
结果
A 组的 RR 为 85.71%，B 组为 41.67%（p=0.0079）。A 组的中位 PFS 为 696.5 天，B 组为 297.5 天（p=0.0326）。A 组的中位 OS 为 1023.4 天，B 组为 518.5 天（p=0.0061）。
结论
CD-DST 可明确化疗耐药和化疗敏感肿瘤。CD-DST 的应用可能是补充治疗开始前知情同意的工具之一。
Zotero 插件